Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01740388 · ClinicalTrials.gov registry record · Phase 3
Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Terminated
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT01740388: Clinical Trial Phase 3 study, sponsored by Bausch & Lomb Incorporated.
NCT01740388 is a Phase 3 study that was terminated before completion, run by Bausch & Lomb Incorporated. The registered enrollment target is 136 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01740388, a Phase 3 study, was terminated before completion, sponsored by Bausch & Lomb Incorporated.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
To evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension, 0.6% (Besifloxacin) administered BID for 3 days compared to vehicle in the treatment of bacterial conjunctivitis.
Primary Outcome
Absence of both conjunctival discharge and bulbar conjunctival injection, after 3 days of treatment with besifloxacin ophthalmic suspension 0.6%
Interventions
- DRUG Vehicle
- DRUG Besifloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Why NCT01740388 stopped before completion
NCT01740388 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT01740388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01740388 about?
NCT01740388 is a clinical study titled "Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis". To evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension, 0.6% (Besifloxacin) administered BID for 3 days compared to vehicle in the treatment of bacterial conjunctivitis.
What is the current status of trial NCT01740388?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2013-02. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01740388?
The interventions under investigation include: Vehicle (DRUG), Besifloxacin (DRUG).
Who is sponsoring clinical trial NCT01740388?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01740388's enrollment target sits among peer trials
136 1580th of 2000 higher than 419 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia